Mark Cragg
Cited by
Cited by
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ...
autophagy 17 (1), 1-382, 2021
Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas
JL Teeling, RR French, MS Cragg, J van den Brakel, M Pluyter, H Huang, ...
Blood 104 (6), 1793-1800, 2004
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
MS Cragg, MJ Glennie
Blood 103 (7), 2738-2743, 2004
Mechanisms of killing by anti-CD20 monoclonal antibodies
MJ Glennie, RR French, MS Cragg, RP Taylor
Molecular immunology 44 (16), 3823-3837, 2007
The biology of CD20 and its potential as a target for mAb therapy
MS Cragg, CA Walshe, AO Ivanov, MJ Glennie
B cell trophic factors and B cell antagonism in autoimmune disease 8, 140-174, 2005
Coupled proliferation and apoptosis maintain the rapid turnover of microglia in the adult brain
K Askew, K Li, A Olmos-Alonso, F Garcia-Moreno, Y Liang, P Richardson, ...
Cell reports 18 (2), 391-405, 2017
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic
J Kuroda, H Puthalakath, MS Cragg, PN Kelly, P Bouillet, DCS Huang, ...
Proceedings of the National Academy of Sciences 103 (40), 14907-14912, 2006
Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics
MS Cragg, J Kuroda, H Puthalakath, DCS Huang, A Strasser
PLoS medicine 4 (10), e316, 2007
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
W Alduaij, A Ivanov, J Honeychurch, EJ Cheadle, S Potluri, SH Lim, ...
Blood, The Journal of the American Society of Hematology 117 (17), 4519-4529, 2011
Anti-CD20 monoclonal antibodies: historical and future perspectives
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135, 2010
CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts
HTC Chan, D Hughes, RR French, AL Tutt, CA Walshe, JL Teeling, ...
Cancer research 63 (17), 5480-5489, 2003
CD20 as a target for therapeutic type I and II monoclonal antibodies
SA Beers, CHT Chan, RR French, MS Cragg, MJ Glennie
Seminars in hematology 47 (2), 107-114, 2010
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
SH Lim, AT Vaughan, M Ashton-Key, EL Williams, SV Dixon, HTC Chan, ...
Blood, The Journal of the American Society of Hematology 118 (9), 2530-2540, 2011
Signaling antibodies in cancer therapy
MS Cragg, RR French, MJ Glennie
Current opinion in immunology 11 (5), 541-547, 1999
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
MS Cragg, C Harris, A Strasser, CL Scott
Nature Reviews Cancer 9 (5), 321-326, 2009
Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells
A Ivanov, SA Beers, CA Walshe, J Honeychurch, W Alduaij, KL Cox, ...
The Journal of clinical investigation 119 (8), 2143-2159, 2009
Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic
MS Cragg, ES Jansen, M Cook, C Harris, A Strasser, CL Scott
The Journal of clinical investigation 118 (11), 3651-3659, 2008
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
SA Beers, CHT Chan, S James, RR French, KE Attfield, CM Brennan, ...
Blood, The Journal of the American Society of Hematology 112 (10), 4170-4177, 2008
The system can't perform the operation now. Try again later.
Articles 1–20